Search

Your search keyword '"Di Cosimo S"' showing total 612 results
Start Over Author "Di Cosimo S"
612 results on '"Di Cosimo S"'

1. Characterization of avalanche photodiodes (APDs) for the CUbesat Solar Polarimeter (CUSP) mission

Author

Cologgi, F., Alimenti, A., Fabiani, S., Torokthii, K., Silva, E., Del Monte, E., Baffo, I., Bonomo, S., Brienza, D., Campana, R., Centrone, M., Contini, G., Costa, E., Curatolo, A., Cucinella, G., DevAngelis, N., De Cesare, G., Del Re, A., Di Cosimo, S., Di Filippo, S., Di Marco, A., Di Persio, G., Donnarumma, I., Fanelli, P., Leonetti, P., Locarini, A., Loffredo, P., Lombardi, G., Minervini, G., Modenini, D., Muleri, F., Natalucci, S., Nigri, A., Perelli, M., Rossi, M., Rubini, A., Scalise, E., Soffitta, P., Terracciano, C., Tortora, P., Zaccagnino, E., and Zambardi, A.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - Solar and Stellar Astrophysics, Physics - Space Physics
Abstract

The CUbesat Solar Polarimeter (CUSP) project is a CubeSat mission orbiting the Earth aimed to measure the linear polarization of solar flares in the hard X-ray band by means of a Compton scattering polarimeter. CUSP will allow the study of the magnetic reconnection and particle acceleration in the flaring magnetic structures of our star. CUSP is a project in the framework of the Alcor Program of the Italian Space Agency aimed at developing new CubeSat missions. It is approved for a Phase B study. In this work, we report on the characterization of the Avalanche Photodiodes (APDs) that will be used as readout sensors of the absorption stage of the Compton polarimeter. We assessed the APDs gain and energy resolution as a function of temperature by irradiating the sensor with a \textsuperscript{55}Fe radioactive source. Moreover, the APDs were also characterized as being coupled to a GAGG scintillator., Comment: Proceeding of SPIE Conference "Astronomical Telescopes+ Instrumentation", Yokohama (Japan), 16-21 June 2024

Published
2024

3. Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients

Author

Tessari A, Palmieri D, and Di Cosimo S

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Anna Tessari,1 Dario Palmieri,2 Serena Di Cosimo11Division of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 2Molecular Biology and Cancer Genetics, Comprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, OH, USAAbstract: Breast cancer includes a body of molecularly distinct subgroups, characterized by different presentation, prognosis, and sensitivity to treatments. Significant advances in our understanding of the complex architecture of this pathology have been achieved in the last few decades, thanks to new biotechnologies that have recently come into the research field and the clinical practice, giving oncologists new instruments that are based on biomarkers and allowing them to set up a personalized approach for each individual patient. Here we review the main treatments available or in preclinical development, the biomolecular diagnostic and prognostic approaches that changed our perspective about breast cancer, giving an overview of targeted therapies that represent the current standard of care for these patients. Finally, we report some examples of how new technologies in clinical practice can set in motion the development of new drugs.Keywords: breast cancer, biomarkers, gene expression profile, next generation sequencing, targeted therapy

Published
2013

4. Design, Construction, and Test of the Gas Pixel Detectors for the IXPE Mission

Author

Baldini, L., Barbanera, M., Bellazzini, R., Bonino, R., Borotto, F., Brez, A., Caporale, C., Cardelli, C., Castellano, S., Ceccanti, M., Citraro, S., Di Lalla, N., Latronico, L., Lucchesi, L., Magazzù, C., Magazzù, G., Maldera, S., Manfreda, A., Marengo, M., Marrocchesi, A., Mereu, P., Minuti, M., Mosti, F., Nasimi, H., Nuti, A., Oppedisano, C., Orsini, L., Pesce-Rollins, M., Pinchera, M., Profeti, A., Sgrò, C., Spandre, G., Tardiola, M., Zanetti, D., Amici, F., Andersson, H., Attinà, P., Bachetti, M., Baumgartner, W., Brienza, D., Carpentiero, R., Castronuovo, M., Cavalli, L., Cavazzuti, E., Centrone, M., Costa, E., D'Alba, E., D'Amico, F., Del Monte, E., Di Cosimo, S., Di Marco, A., Di Persio, G., Donnarumma, I., Evangelista, Y., Fabiani, S., Ferrazzoli, R., Kitaguchi, T., La Monaca, F., Lefevre, C., Loffredo, P., Lorenzi, P., Mangraviti, E., Matt, G., Meilahti, T., Morbidini, A., Muleri, F., Nakano, T., Negri, B., Nenonen, S., O'Dell, S. L., Perri, M., Piazzolla, R., Pieraccini, S., Pilia, M., Puccetti, S., Ramsey, B. D., Rankin, J., Ratheesh, A., Rubini, A., Santoli, F., Sarra, P., Scalise, E., Sciortino, A., Soffitta, P., Tamagawa, T., Tennant, A. F., Tobia, A., Trois, A., Uchiyama, K., Vimercati, M., Weisskopf, M. C., Xie, F., Zanetti, F., and Zhou, Y.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - High Energy Astrophysical Phenomena, Physics - Instrumentation and Detectors
Abstract

Due to be launched in late 2021, the Imaging X-Ray Polarimetry Explorer (IXPE) is a NASA Small Explorer mission designed to perform polarization measurements in the 2-8 keV band, complemented with imaging, spectroscopy and timing capabilities. At the heart of the focal plane is a set of three polarization-sensitive Gas Pixel Detectors (GPD), each based on a custom ASIC acting as a charge-collecting anode. In this paper we shall review the design, manufacturing, and test of the IXPE focal-plane detectors, with particular emphasis on the connection between the science drivers, the performance metrics and the operational aspects. We shall present a thorough characterization of the GPDs in terms of effective noise, trigger efficiency, dead time, uniformity of response, and spectral and polarimetric performance. In addition, we shall discuss in detail a number of instrumental effects that are relevant for high-level science analysis -- particularly as far as the response to unpolarized radiation and the stability in time are concerned., Comment: To be published in Astroparticle Physics

Published
2021
Full Text
View/download PDF

9. eXTP -- enhanced X-ray Timing and Polarimetry Mission

Author

Zhang, S. N., Feroci, M., Santangelo, A., Dong, Y. W., Feng, H., Lu, F. J., Nandra, K., Wang, Z. S., Zhang, S., Bozzo, E., Brandt, S., De Rosa, A., Gou, L. J., Hernanz, M., van der Klis, M., Li, X. D., Liu, Y., Orleanski, P., Pareschi, G., Pohl, M., Poutanen, J., Qu, J. L., Schanne, S., Stella, L., Uttley, P., Watts, A., Xu, R. X., Yu, W. F., Zand, J. J. M. in 't, Zane, S., Alvarez, L., Amati, L., Baldini, L., Bambi, C., Basso, S., Bhattacharyya, S., Bellazzini, R., Belloni, T., Bellutti, P., Bianchi, S., Brez, A., Bursa, M., Burwitz, V., Budtz-Jorgensen, C., Caiazzo, I., Campana, R., Cao, X. L., Casella, P., Chen, C. Y., Chen, L., Chen, T. X., Chen, Y., Chen, Y. P., Civitani, M., Zelati, F. Coti, Cui, W., Cui, W. W., Dai, Z. G., Del Monte, E., De Martino, D., Di Cosimo, S., Diebold, S., Dovciak, M., Donnarumma, I., Doroshenko, V., Esposito, P., Evangelista, Y., Favre, Y., Friedrich, P., Fuschino, F., Galvez, J. L., Gao, Z. L., Ge, M. Y., Gevin, O., Goetz, D., Han, D. W., Heyl, J., Horak, J., Hu, W., Huang, F., Huang, Q. S., Hudec, R., Huppenkothen, D., Israel, G. L., Ingram, A., Karas, V., Karelin, D., Jenke, P. A., Ji, L., Kennedy, T., Korpela, S., Kunneriath, D., Labanti, C., Li, G., Li, X., Li, Z. S., Liang, E. W., Limousin, O., Lin, L., Ling, Z. X., Liu, H. B., Liu, H. W., Liu, Z., Lu, B., Lund, N., Lai, D., Luo, B., Luo, T., Ma, B., Mahmoodifar, S., Marisaldi, M., Martindale, A., Meidinger, N., Men, Y. P., Michalska, M., Mignani, R., Minuti, M., Motta, S., Muleri, F., Neilsen, J., Orlandini, M., Pan, A T., Patruno, A., Perinati, E., Picciotto, A., Piemonte, C., Pinchera, M., Rachevski, A., Rapisarda, M., Rea, N., Rossi, E. M. R., Rubini, A., Sala, G., Shu, X. W., Sgro, C., Shen, Z. X., Soffitta, P., Song, L. M., Spandre, G., Stratta, G., Strohmayer, T. E., Sun, L., Svoboda, J., Tagliaferri, G., Tenzer, C., Tong, H., Taverna, R., Torok, G., Turolla, R., Vacchi, A., Wang, J., Wang, J. X., Walton, D., Wang, K., Wang, J. F., Wang, R. J., Wang, Y. F., Weng, S. S., Wilms, J., Winter, B., Wu, X., Wu, X. F., Xiong, S. L., Xu, Y. P., Xue, Y. Q., Yan, Z., Yang, S., Yang, X., Yang, Y. J., Yuan, F., Yuan, W. M., Yuan, Y. F., Zampa, G., Zampa, N., Zdziarski, A., Zhang, C., Zhang, C. L., Zhang, L., Zhang, X., Zhang, Z., Zhang, W. D., Zheng, S. J., Zhou, P., and Zhou, X. L.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - High Energy Astrophysical Phenomena
Abstract

eXTP is a science mission designed to study the state of matter under extreme conditions of density, gravity and magnetism. Primary targets include isolated and binary neutron stars, strong magnetic field systems like magnetars, and stellar-mass and supermassive black holes. The mission carries a unique and unprecedented suite of state-of-the-art scientific instruments enabling for the first time ever the simultaneous spectral-timing-polarimetry studies of cosmic sources in the energy range from 0.5-30 keV (and beyond). Key elements of the payload are: the Spectroscopic Focusing Array (SFA) - a set of 11 X-ray optics for a total effective area of about 0.9 m^2 and 0.6 m^2 at 2 keV and 6 keV respectively, equipped with Silicon Drift Detectors offering <180 eV spectral resolution; the Large Area Detector (LAD) - a deployable set of 640 Silicon Drift Detectors, for a total effective area of about 3.4 m^2, between 6 and 10 keV, and spectral resolution <250 eV; the Polarimetry Focusing Array (PFA) - a set of 2 X-ray telescope, for a total effective area of 250 cm^2 at 2 keV, equipped with imaging gas pixel photoelectric polarimeters; the Wide Field Monitor (WFM) - a set of 3 coded mask wide field units, equipped with position-sensitive Silicon Drift Detectors, each covering a 90 degrees x 90 degrees FoV. The eXTP international consortium includes mostly major institutions of the Chinese Academy of Sciences and Universities in China, as well as major institutions in several European countries and the United States. The predecessor of eXTP, the XTP mission concept, has been selected and funded as one of the so-called background missions in the Strategic Priority Space Science Program of the Chinese Academy of Sciences since 2011. The strong European participation has significantly enhanced the scientific capabilities of eXTP. The planned launch date of the mission is earlier than 2025., Comment: 16 pages, 16 figures. Oral talk presented at SPIE Astronomical Telescopes and Instrumentation, June 26 to July 1, 2016, Edingurgh, UK

Published
2016
Full Text
View/download PDF

11. Managing the mass production for the LAD instrument onboard eXTP

Author

Egner, Sébastien E., Roberts, Scott, Minervini, G., Argan, A., Feroci, M., Trois, A., Del Monte, E., Brienza, D., Ambrosi, G., Antonelli, M., Barbera, M., Baudin, D., Bayer, J., Bellutti, P., Bertucci, B., Bi, Xingzi, Bonvicini, W., Bozzo, E., Bouyjou, F., Cadoux, F., Campana, R., Cao, Jiewei, Cavazzuti, E., Ceraudo, F., Chen, Tianxiang, Chen, Wen, Cirrincione, D., Collura, A., D'Anca, F., De Angelis, N., De Rosa, A., Di Cosimo, S., Didillo, G., Evangelista, Y., Favre, Y., Fiandrini, E., Ficorella, F., Gao, Na, Gevin, O., Guedel, M., Han, Xingbo, He, Huilin, Hedderman, P., Hynek, R., Kole, M., Karas, V., Komarek, M., La Marra, D., Liang, Hong, Limousin, O., Liu, Rui, Lo Cicero, U., Loehring, J., Lombardi, G., Lu, Fang-Jun, Luo, Tao, Merkl, M., Meuris, A., Michalska, M., Morgante, G., Munini, R., Mussolin, L., Novák, P., Nowosielski, W., Nuti, A., Orleanski, P., Ottensamer, R., Pacciani, L., Paltani, S., Pepponi, G., Piazzolla, R., Picciotto, A., Pliego Caballero, S., Putz, A., Rachevski, A., Rashevskaya, I., Samusenko, A., Santangelo, A., Schanne, S., Sciortino, L., Skup, K., Sveda, L., Svoboda, J., Tenzer, C., Todaro, M., Vacchi, A., Xiong, Hao, Wang, Jian, Wang, Xianqi, Winter, B., Wu, Xin, Zampa, G., Zampa, N., Zdziarski, A. A., Zhang, Shu-Nan, Zhang, Xiaoli, Zhang, Zhen, Zhao, Zijian, Zhou, Yupeng, and Zorzi, N.

Published
2024
Full Text
View/download PDF

13. The Large Area Detector of LOFT: the Large Observatory for X-ray Timing

Author

Zane, S., Walton, D., Kennedy, T., Feroci, M., Herder, J. -W. Den, Ahangarianabhari, M., Argan, A., Azzarello, P., Baldazzi, G., Barbera, M., Barret, D., Bertuccio, G., Bodin, P., Bozzo, E., Bradley, L., Cadoux, F., Cais, P., Campana, R., Coker, J., Cros, A., Del Monte, E., De Rosa, A., Di Cosimo, S., Donnarumma, I., Evangelista, Y., Favre, Y., Feldman, C., Fraser, G., Fuschino, F., Grassi, M., Hailey, M. R., Hudec, R., Labanti, C., Macera, D., Malcovati, P., Marisaldi, M., Martindale, A., Mineo, T., Muleri, F., Nowak, M., Orlandini, M., Pacciani, L., Perinati, E., Petracek, V., Pohl, M., Rachevski, A., Smith, P., Santangelo, A., Seyler, J. -Y., Schmid, C., Soffitta, P., Suchy, S., Tenzer, C., Uttley, P., Vacchi, A., Zampa, G., Zampa, N., Wilms, J., and Winter, B.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

LOFT (Large Observatory for X-ray Timing) is one of the five candidates that were considered by ESA as an M3 mission (with launch in 2022-2024) and has been studied during an extensive assessment phase. It is specifically designed to perform fast X-ray timing and probe the status of the matter near black holes and neutron stars. Its pointed instrument is the Large Area Detector (LAD), a 10 m 2 -class instrument operating in the 2-30keV range, which holds the capability to revolutionise studies of variability from X-ray sources on the millisecond time scales. The LAD instrument has now completed the assessment phase but was not down-selected for launch. However, during the assessment, most of the trade-offs have been closed leading to a robust and well documented design that will be re- proposed in future ESA calls. In this talk, we will summarize the characteristics of the LAD design and give an overview of the expectations for the instrument capabilities., Comment: Proc. SPIE 9144, Space Telescopes and Instrumentation 2014: Ultraviolet to Gamma Ray, 91442W

Published
2014
Full Text
View/download PDF

14. The Large Observatory For x-ray Timing

Author

Feroci, M., Herder, J. W. den, Bozzo, E., Barret, D., Brandt, S., Hernanz, M., van der Klis, M., Pohl, M., Santangelo, A., Stella, L., Watts, A., Wilms, J., Zane, S., Ahangarianabhari, M., Albertus, C., Alford, M., Alpar, A., Altamirano, D., Alvarez, L., Amati, L., Amoros, C., Andersson, N., Antonelli, A., Argan, A., Artigue, R., Artigues, B., Atteia, J. -L., Azzarello, P., Bakala, P., Baldazzi, G., Balman, S., Barbera, M., van Baren, C., Bhattacharyya, S., Baykal, A., Belloni, T., Bernardini, F., Bertuccio, G., Bianchi, S., Bianchini, A., Binko, P., Blay, P., Bocchino, F., Bodin, P., Bombaci, I., Bidaud, J. -M. Bonnet, Boutloukos, S., Bradley, L., Braga, J., Brown, E., Bucciantini, N., Burderi, L., Burgay, M., Bursa, M., Budtz-Jørgensen, C., Cackett, E., Cadoux, F. R., Cais, P., Caliandro, G. A., Campana, R., Campana, S., Capitanio, F., Casares, J., Casella, P., Castro-Tirado, A. J., Cavazzuti, E., Cerda-Duran, P., Chakrabarty, D., Château, F., Chenevez, J., Coker, J., Cole, R., Collura, A., Cornelisse, R., Courvoisier, T., Cros, A., Cumming, A., Cusumano, G., D'Aì, A., D'Elia, V., Del Monte, E., De Luca, A., De Martino, D., Dercksen, J. P. C., De Pasquale, M., De Rosa, A., Del Santo, M., Di Cosimo, S., Diebold, S., Di Salvo, T., Donnarumma, I., Drago, A., Durant, M., Emmanoulopoulos, D., Erkut, M. H., Esposito, P., Evangelista, Y., Fabian, A., Falanga, M., Favre, Y., Feldman, C., Ferrari, V., Ferrigno, C., Finger, M., Finger, M. H., Fraser, G. W., Frericks, M., Fuschino, F., Gabler, M., Galloway, D. K., Sanchez, J. L. Galvez, Garcia-Berro, E., Gendre, B., Gezari, S., Giles, A. B., Gilfanov, M., Giommi, P., Giovannini, G., Giroletti, M., Gogus, E., Goldwurm, A., Goluchová, K., Götz, D., Gouiffes, C., Grassi, M., Groot, P., Gschwender, M., Gualtieri, L., Guidorzi, C., Guy, L., Haas, D., Haensel, P., Hailey, M., Hansen, F., Hartmann, D. H., Haswell, C. A., Hebeler, K., Heger, A., Hermsen, W., Homan, J., Hornstrup, A., Hudec, R., Huovelin, J., Ingram, A., Zand, J. J. M. in't, Israel, G., Iwasawa, K., Izzo, L., Jacobs, H. M., Jetter, F., Johannsen, T., Jonker, P., Josè, J., Kaaret, P., Kanbach, G., Karas, V., Karelin, D., Kataria, D., Keek, L., Kennedy, T., Klochkov, D., Kluzniak, W., Kokkotas, K., Korpela, S., Kouveliotou, C., Kreykenbohm, I., Kuiper, L. M., Kuvvetli, I., Labanti, C., Lai, D., Lamb, F. K., Laubert, P. P., Lebrun, F., Lin, D., Linder, D., Lodato, G., Longo, F., Lund, N., Maccarone, T. J., Macera, D., Maestre, S., Mahmoodifar, S., Maier, D., Malcovati, P., Mandel, I., Mangano, V., Manousakis, A., Marisaldi, M., Markowitz, A., Martindale, A., Matt, G., McHardy, I. M., Melatos, A., Mendez, M., Mereghetti, S., Michalska, M., Migliari, S., Mignani, R., Miller, M. C., Miller, J. M., Mineo, T., Miniutti, G., Morsink, S., Motch, C., Motta, S., Mouchet, M., Mouret, G., Mulačová, J., Muleri, F., Muñoz-Darias, T., Negueruela, I., Neilsen, J., Norton, A. J., Nowak, M., O'Brien, P., Olsen, P. E. H., Orienti, M., Orio, M., Orlandini, M., Orleanski, P., Osborne, J. P., Osten, R., Ozel, F., Pacciani, L., Paolillo, M., Papitto, A., Paredes, J. M., Patruno, A., Paul, B., Perinati, E., Pellizzoni, A., Penacchioni, A. V., Perez, M. A., Petracek, V., Pittori, C., Pons, J., Portell, J., Possenti, A., Poutanen, J., Prakash, M., Provost, P. Le, Psaltis, D., Rambaud, D., Ramon, P., Ramsay, G., Rapisarda, M., Rachevski, A., Rashevskaya, I., Ray, P. S., Rea, N., Reddy, S., Reig, P., Aranda, M. Reina, Remillard, R., Reynolds, C., Rezzolla, L., Ribo, M., de la Rie, R., Riggio, A., Rios, A., Gil, P. Rodríguez, Rodriguez, J., Rohlfs, R., Romano, P., Rossi, E. M. R., Rozanska, A., Rousseau, A., Ryde, F., Sabau-Graziati, L., Sala, G., Salvaterra, R., Sanna, A., Sandberg, J., Scaringi, S., Schanne, S., Schee, J., Schmid, C., Shore, S., Schneider, R., Schwenk, A., Schwope, A. D., Seyler, J. -Y., Shearer, A., Smith, A., Smith, D. M., Smith, P. J., Sochora, V., Soffitta, P., Soleri, P., Spencer, A., Stappers, B., Steiner, A. W., Stergioulas, N., Stratta, G., Strohmayer, T. E., Stuchlik, Z., Suchy, S., Sulemainov, V., Takahashi, T., Tamburini, F., Tauris, T., Tenzer, C., Tolos, L., Tombesi, F., Tomsick, J., Torok, G., Torrejon, J. M., Torres, D. F., Tramacere, A., Trois, A., Turolla, R., Turriziani, S., Uter, P., Uttley, P., Vacchi, A., Varniere, P., Vaughan, S., Vercellone, S., Vrba, V., Walton, D., Watanabe, S., Wawrzaszek, R., Webb, N., Weinberg, N., Wende, H., Wheatley, P., Wijers, R., Wijnands, R., Wille, M., Wilson-Hodge, C. A., Winter, B., Wood, K., Zampa, G., Zampa, N., Zampieri, L., Zdunik, L., Zdziarski, A., Zhang, B., Zwart, F., Ayre, M., Boenke, T., van Damme, C. Corral, Kuulkers, E., and Lumb, D.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

The Large Observatory For x-ray Timing (LOFT) was studied within ESA M3 Cosmic Vision framework and participated in the final down-selection for a launch slot in 2022-2024. Thanks to the unprecedented combination of effective area and spectral resolution of its main instrument, LOFT will study the behaviour of matter under extreme conditions, such as the strong gravitational field in the innermost regions of accretion flows close to black holes and neutron stars, and the supra-nuclear densities in the interior of neutron stars. The science payload is based on a Large Area Detector (LAD, 10 m 2 effective area, 2-30 keV, 240 eV spectral resolution, 1 deg collimated field of view) and a WideField Monitor (WFM, 2-50 keV, 4 steradian field of view, 1 arcmin source location accuracy, 300 eV spectral resolution). The WFM is equipped with an on-board system for bright events (e.g. GRB) localization. The trigger time and position of these events are broadcast to the ground within 30 s from discovery. In this paper we present the status of the mission at the end of its Phase A study., Comment: Proc. SPIE 9144, Space Telescopes and Instrumentation 2014: Ultraviolet to Gamma Ray, 91442T

Published
2014
Full Text
View/download PDF

18. A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy

Author

Zambelli, A, Cazzaniga, M, La Verde, N, Munzone, E, Antonazzo, I, Mantovani, L, Di Cosimo, S, Mancuso, A, Generali, D, Cortesi, P, Zambelli A., Cazzaniga M., La Verde N., Munzone E., Antonazzo I. C., Mantovani L. G., Di Cosimo S., Mancuso A., Generali D., Cortesi P. A., Zambelli, A, Cazzaniga, M, La Verde, N, Munzone, E, Antonazzo, I, Mantovani, L, Di Cosimo, S, Mancuso, A, Generali, D, Cortesi, P, Zambelli A., Cazzaniga M., La Verde N., Munzone E., Antonazzo I. C., Mantovani L. G., Di Cosimo S., Mancuso A., Generali D., and Cortesi P. A.

Abstract

Introduction: Clinical trials confirmed the beneficial effects of adding pertuzumab (P) to the combination of trastuzumab-chemotherapy (TC) in the (neo)adjuvant setting of high-risk HER2-positive early breast cancer (HER2+BC). We evaluated the clinical, economic and societal impact of adding pertuzumab to neoadjuvant TC combination (TPC) in Italy. Methods: A cost-consequence analysis comparing TPC vs. TC was performed developing a cohort-based multi-state Markov model to estimate the clinical, societal and economic impact of the neoadjuvant therapy of TPC versus TC in HER2+BC at high-risk of recurrence. The model works on a cycle length of 1 month and 5-years-time horizon. Literature review-based data were used to populate the model. The following clinical and economic outcomes were estimated: cumulative incidence of loco-regional/distant recurrences, life of years and QALY and both direct and indirect costs (€). Finally, sensitivity analyses were performed. Results: TPC was associated with a 75,630 € saved of direct costs. Specifically, it was associated with an initial increase of treatment costs (+4.8%) followed by reduction of recurrence management cost (−20.4%). TPC was also associated with an indirect cost reduction of 1.40%, as well as decreased incidence of distant recurrence (−20.14%), days of work lost (−1.53%) and days lived with disability (−0.50%). Furthermore, TPC reported 10,47 QALY gained (+2.77%) compared to TC. The probability to achieve the pathological complete response (pCR) was the parameter that mostly affected the results in the sensitivity analysis. Conclusion: Our findings suggested that TPC combination could be a cost-saving option in patients with HER2+BC at high-risk of recurrence.

Published
2023

19. LOFT: the Large Observatory For X-ray Timing

Author

Feroci, M., Herder, J. W. den, Bozzo, E., Barret, D., Brandt, S., Hernanz, M., van der Klis, M., Pohl, M., Santangelo, A., Stella, L., Watts, A., Wilms, J., Zane, S., Ahangarianabhari, M., Alpar, A., Altamirano, D., Alvarez, L., Amati, L., Amoros, C., Andersson, N., Antonelli, A., Argan, A., Artigue, R., Azzarello, P., Baldazzi, G., Balman, S., Barbera, M., Belloni, T., Bertuccio, G., Bianchi, S., Bianchini, A., Bodin, P., Bidaud, J. -M. Bonnet, Boutloukos, S., Braga, J., Brown, E., Bucciantini, N., Burderi, L., Bursa, M., Budtz-Jørgensen, C., Cackett, E., Cadoux, F. R., Cais, P., Caliandro, G. A., Campana, R., Campana, S., Casella, P., Chakrabarty, D., Chenevez, J., Coker, J., Cole, R., Collura, A., Courvoisier, T., Cros, A., Cumming, A., Cusumano, G., D'Aì, A., D'Elia, V., Del Monte, E., De Martino, D., De Rosa, A., Di Cosimo, S., Diebold, S., Di Salvo, T., Donnarumma, I., Drago, A., Durant, M., Emmanoulopoulos, D., Evangelista, Y., Fabian, A., Falanga, M., Favre, Y., Feldman, C., Ferrigno, C., Finger, M. H., Fraser, G. W., Fuschino, F., Galloway, D. K., Sanchez, J. L. Galvez, Garcia-Berro, E., Gendre, B., Gezari, S., Giles, A. B., Gilfanov, M., Giommi, P., Giovannini, G., Giroletti, M., Goldwurm, A., Götz, D., Gouiffes, C., Grassi, M., Guidorzi, P. Groot C., Haas, D., Hansen, F., Hartmann, D. H., Haswe, C. A., Heger, A., Homan, J., Hornstrup, A., Hudec, R., Huovelin, J., Ingram, A., Zand, J. J. M. in't, Isern, J., Israe, G., Izzo, L., Jonker, P., Kaaret, P., Karas, V., Karelin, D., Kataria, D., Keek, L., Kennedy, T., Klochkov, D., Kluzniak, W., Kokkotas, K., Korpela, S., Kouveliotou, C., Kreykenbohm, I., Kuiper, L. M., Kuvvetli, I., Labanti, C., Lai, D., Lamb, F. K., Lebrun, F., Lin, D., Linder, D., Lodato, G., Longo, F., Lund, N., Maccarone, T. J., Macera, D., Maier, D., Malcovati, P., Mangano, V., Manousakis, A., Marisaldi, M., Markowitz, A., Martindale, A., Matt, G., McHardy, I. M., Melatos, A., Mendez, M., Migliari, S., Mignani, R., Miller, M. C., Miller, J. M., Mineo, T., Miniutti, G., Morsink, S., Motch, C., Motta, S., Mouchet, M., Muleri, F., Norton, A. J., Nowak, M., O'Brien, P., Orienti, M., Orio, M., Orlandini, M., Orleanski, P., Osborne, J. P., Osten, R., Ozel, F., Pacciani, L., Papitto, A., Paul, B., Perinati, E., Petracek, V., Portell, J., Poutanen, J., Psaltis, D., Rambaud, D., Ramsay, G., Rapisarda, M., Rachevski, A., Ray, P. S., Rea, N., Reddy, S., Reig, P., Aranda, M. Reina, Remillard, R., Reynolds, C., Rodríguez-Gil, P., Rodriguez, J., Romano, P., Rossi, E. M. R., Ryde, F., Sabau-Graziati, L., Sala, G., Salvaterra, R., Sanna, A., Schanne, S., Schee, J., Schmid, C., Schwenk, A., Schwope, A. D., Seyler, J. -Y., Shearer, A., Smith, A., Smith, D. M., Smith, P. J., Sochora, V., Soffitta, P., Soleri, P., Stappers, B., Stelzer, B., Stergioulas, N., Stratta, G., Strohmayer, T. E., Stuchlik, Z., Suchy, S., Sulemainov, V., Takahashi, T., Tamburini, F., Tenzer, C., Tolos, L., Torok, G., Torrejon, J. M., Torres, D. F., Tramacere, A., Trois, A., Turriziani, S., Uter, P., Uttley, P., Vacchi, A., Varniere, P., Vaughan, S., Vercellone, S., Vrba, V., Walton, D., Watanabe, S., Wawrzaszek, R., Webb, N., Weinberg, N., Wende, H., Wheatley, P., Wijers, R., Wijnands, R., Wille, M., Wilson-Hodge, C. A., Winter, B., Wood, K., Zampa, G., Zampa, N., Zampieri, L., Zdziarski, A., and Zhang, B.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

The LOFT mission concept is one of four candidates selected by ESA for the M3 launch opportunity as Medium Size missions of the Cosmic Vision programme. The launch window is currently planned for between 2022 and 2024. LOFT is designed to exploit the diagnostics of rapid X-ray flux and spectral variability that directly probe the motion of matter down to distances very close to black holes and neutron stars, as well as the physical state of ultra-dense matter. These primary science goals will be addressed by a payload composed of a Large Area Detector (LAD) and a Wide Field Monitor (WFM). The LAD is a collimated (<1 degree field of view) experiment operating in the energy range 2-50 keV, with a 10 m^2 peak effective area and an energy resolution of 260 eV at 6 keV. The WFM will operate in the same energy range as the LAD, enabling simultaneous monitoring of a few-steradian wide field of view, with an angular resolution of <5 arcmin. The LAD and WFM experiments will allow us to investigate variability from submillisecond QPO's to year-long transient outbursts. In this paper we report the current status of the project., Comment: Proceedings of SPIE, Vol. 8443, Paper No. 8443-85, 2012

Published
2012
Full Text
View/download PDF

20. A Large Area Detector proposed for the Large Observatory for X-ray Timing (LOFT)

Author

Zane, S., Walton, D., Kennedy, T., Feroci, M., Herder, J. -W. Den, Ahangarianabhari, M., Argan, A., Azzarello, P., Baldazzi, G., Barret, D., Bertuccio, G., Bodini, P., Bozzo, E., Cadoux, F., Cais, P., Campana, R., Coker, J., Cros, A., Del Monte, E., De Rosa, A., Di Cosimo, S., Donnarumma, I., Evangelista, Y., Favre, Y., Feldman, C., Fraser, G., Fuschino, F., Grassi, M., Hailey, M. R., Hudec, R., Labanti, C., Macera, D., Malcovati, P., Marisaldi, M., Martindale, A., Mineo, T., Muleri, F., Nowak, M., Orlandini, M., Pacciani, L., Perinati, E., Petracek, V., Pohl, M., Rachevski, A., Smith, P., Santangelo, A., Seyler, J. -Y., Schmid, C., Soffitta, P., Suchy, S., Tenzer, C., Uttley, P., Vacchi, A., Zampa, G., Zampa, N., Wilms, J., and Winter, B.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

The Large Observatory for X-ray Timing (LOFT) is one of the four candidate ESA M3 missions considered for launch in the 2022 time-frame. It is specifically designed to perform fast X-ray timing and probe the status of the matter near black holes and neutron stars. The LOFT scientific payload is composed of a Large Area Detector (LAD) and a Wide Field Monitor (WFM). The LAD is a 10 m2-class pointed instrument with 20 times the collecting area of the best past timing missions (such as RXTE) over the 2-30 keV range, which holds the capability to revolutionize studies of X-ray variability down to the millisecond time scales. Its ground-breaking characteristic is a low mass per unit surface, enabling an effective area of ~10 m^2 (@10 keV) at a reasonable weight. The development of such large but light experiment, with low mass and power per unit area, is now made possible by the recent advancements in the field of large-area silicon detectors - able to time tag an X-ray photon with an accuracy <10 {\mu}s and an energy resolution of ~260 eV at 6 keV - and capillary-plate X-ray collimators. In this paper, we will summarize the characteristics of the LAD instrument and give an overview of its capabilities., Comment: Proceedings of SPIE, Vo. 8443, Paper No. 8443-87

Published
2012
Full Text
View/download PDF

21. ORIGIN: Metal Creation and Evolution from the Cosmic Dawn

Author

Herder, J. W. den, Piro, L., Ohashi, T., Kouveliotou, C., Hartmann, D. H., Kaastra, J. S., Amati, L., Andersen, M. I., Arnaud, M., Attéia, J-L., Bandler, S., Barbera, M., Barcons, X., Barthelmy, S., Basa, S., Basso, S., Boer, M., Branchini, E., Branduardi-Raymont, G., Borgani, S., Boyarsky, A., Brunetti, G., Budtz-Jorgensen, C., Burrows, D., Butler, N., Campana, S., Caroli, E., Ceballos, M., Christensen, F., Churazov, E., Comastri, A., Colasanti, L., Cole, R., Content, R., Corsi, A., Costantini, E., Conconi, P., Cusumano, G., de Plaa, J., De Rosa, A., Del Santo, M., Di Cosimo, S., De Pasquale, M., Doriese, R., Ettori, S., Evans, P., Ezoe, Y., Ferrari, L., Finger, H., Figueroa-Feliciano, T., Friedrich, P., Fujimoto, R., Furuzawa, A., Fynbo, J., Gatti, F., Galeazzi, M., Gehrels, N., Gendre, B., Ghirlanda, G., Ghisellini, G., Gilfanov, M., Giommi, P., Girardi, M., Grindlay, J., Cocchi, M., Godet, O., Guedel, M., Haardt, F., Hartog, R. den, Hepburn, I., Hermsen, W., Hjorth, J., Hoekstra, H., Holland, A., Hornstrup, A., van der Horst, A., Hoshino, A., Zand, J. in 't, Irwin, K., Ishisaki, Y., Jonker, P., Kitayama, T., Kawahara, H., Kawai, N., Kelley, R., Kilbourne, C., de Korte, P., Kusenko, A., Kuvvetli, I., Labanti, M., Macculi, C., Maiolino, R., Hesse, M. Mas, Matsushita, K., Mazzotta, P., McCammon, D., Méndez, M., Mignani, R., Mineo, T., Mitsuda, K., Mushotzky, R., Molendi, S., Moscardini, L., Natalucci, L., Nicastro, F., O'Brien, P., Osborne, J., Paerels, F., Page, M., Paltani, S., Pedersen, K., Perinati, E., Ponman, T., Pointecouteau, E., Predehl, P., Porter, S., Rasmussen, A., Rauw, G., Röttgering, H., Roncarelli, M., Rosati, P., Quadrini, E., Ruchayskiy, O., Salvaterra, R., Sasaki, S., Sato, K., Savaglio, S., Schaye, J., Sciortino, S., Shaposhnikov, M., Sharples, R., Shinozaki, K., Spiga, D., Sunyaev, R., Suto, Y., Takei, Y., Tanvir, N., Tashiro, M., Tamura, T., Tawara, Y., Troja, E., Tsujimoto, M., Tsuru, T., Ubertini, P., Ullom, J., Ursino, E., Verbunt, F., van de Voort, F., Viel, M., Wachter, S., Watson, D., Weisskopf, M., Werner, N., White, N., Willingale, R., Wijers, R., Yamasaki, N., Yoshikawa, K., and Zane, S.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - Cosmology and Extragalactic Astrophysics, Astrophysics - High Energy Astrophysical Phenomena
Abstract

ORIGIN is a proposal for the M3 mission call of ESA aimed at the study of metal creation from the epoch of cosmic dawn. Using high-spectral resolution in the soft X-ray band, ORIGIN will be able to identify the physical conditions of all abundant elements between C and Ni to red-shifts of z=10, and beyond. The mission will answer questions such as: When were the first metals created? How does the cosmic metal content evolve? Where do most of the metals reside in the Universe? What is the role of metals in structure formation and evolution? To reach out to the early Universe ORIGIN will use Gamma-Ray Bursts (GRBs) to study their local environments in their host galaxies. This requires the capability to slew the satellite in less than a minute to the GRB location. By studying the chemical composition and properties of clusters of galaxies we can extend the range of exploration to lower redshifts (z ~ 0.2). For this task we need a high-resolution spectral imaging instrument with a large field of view. Using the same instrument, we can also study the so far only partially detected baryons in the Warm-Hot Intergalactic Medium (WHIM). The less dense part of the WHIM will be studied using absorption lines at low redshift in the spectra for GRBs., Comment: 34 pages, 13 figures. ESA Cosmic Vision medium-class mission (M3) proposal. Accepted for publication in Experimental Astronomy. Including minor corrections in the author list

Published
2011
Full Text
View/download PDF

22. LOFT - a Large Observatory For x-ray Timing

Author

Feroci, M., Stella, L., Vacchi, A., Labanti, C., Rapisarda, M., Attinà, P., Belloni, T., Campana, R., Campana, S., Costa, E., Del Monte, E., Donnarumma, I., Evangelista, Y., Israel, G. L., Muleri, F., Porta, P., Rashevsky, A., Zampa, G., Zampa, N., Baldazzi, G., Bertuccio, G., Bonvicini, V., Bozzo, E., Burderi, L., Corongiu, A., Covino, S., Dall'Osso, S., De Martino, D., Di Cosimo, S., Di Persio, G., Di Salvo, T., Fuschino, F., Grassi, M., Lazzarotto, F., Malcovati, P., Marisaldi, M., Mastropietro, M., Mereghetti, S., Morelli, E., Orio, M., Pellizzoni, A., Pacciani, L., Papitto, A., Picolli, L., Possenti, A., Rubini, A., Soffitta, P., Turolla, R., and Zampieri, L.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - High Energy Astrophysical Phenomena
Abstract

The high time resolution observations of the X-ray sky hold the key to a number of diagnostics of fundamental physics, some of which are unaccessible to other types of investigations, such as those based on imaging and spectroscopy. Revealing strong gravitational field effects, measuring the mass and spin of black holes and the equation of state of ultradense matter are among the goals of such observations. At present prospects for future, non-focused X-ray timing experiments following the exciting age of RXTE/PCA are uncertain. Technological limitations are unavoidably faced in the conception and development of experiments with effective area of several square meters, as needed in order to meet the scientific requirements. We are developing large-area monolithic Silicon Drift Detectors offering high time and energy resolution at room temperature, which require modest resources and operation complexity (e.g., read-out) per unit area. Based on the properties of the detector and read-out electronics that we measured in the lab, we developed a realistic concept for a very large effective area mission devoted to X-ray timing in the 2-30 keV energy range. We show that effective areas in the range of 10-15 square meters are within reach, by using a conventional spacecraft platform and launcher of the small-medium class., Comment: 13 pages, 8 figures, 1 table, Proceedings of SPIE Vol. 7732, Paper No. 7732-66, 2010

Published
2010
Full Text
View/download PDF

24. The Large Observatory for x-ray timing

Author

Feroci, M, Herder, JW den, Bozzo, E, Barret, D, Brandt, S, Hernanz, M, van der Klis, M, Pohl, M, Santangelo, A, Stella, L, Watts, A, Wilms, J, Zane, S, Ahangarianabhari, M, Albertus, C, Alford, M, Alpar, A, Altamirano, D, Alvarez, L, Amati, L, Amoros, C, Andersson, N, Antonelli, A, Argan, A, Artigue, R, Artigues, B, Atteia, J-L, Azzarello, P, Bakala, P, Baldazzi, G, Balman, S, Barbera, M, van Baren, C, Bhattacharyya, S, Baykal, A, Belloni, T, Bernardini, F, Bertuccio, G, Bianchi, S, Bianchini, A, Binko, P, Blay, P, Bocchino, F, Bodin, P, Bombaci, I, Bidaud, J-M Bonnet, Boutloukos, S, Bradley, L, Braga, J, Brown, E, Bucciantini, N, Burderi, L, Burgay, M, Bursa, M, Budtz-Jørgensen, C, Cackett, E, Cadoux, FR, Caïs, P, Caliandro, GA, Campana, R, Campana, S, Capitanio, F, Casares, J, Casella, P, Castro-Tirado, AJ, Cavazzuti, E, Cerda-Duran, P, Chakrabarty, D, Château, F, Chenevez, J, Coker, J, Cole, R, Collura, A, Cornelisse, R, Courvoisier, T, Cros, A, Cumming, A, Cusumano, G, D'Ai, A, D'Elia, V, Del Monte, E, de Luca, A, de Martino, D, Dercksen, JPC, de Pasquale, M, De Rosa, A, Del Santo, M, Di Cosimo, S, Diebold, S, Di Salvo, T, Donnarumma, I, Drago, A, Durant, M, Emmanoulopoulos, D, Erkut, MH, Esposito, P, Evangelista, Y, Fabian, A, Falanga, M, and Favre, Y

Subjects
X-ray timing, X-ray spectroscopy, X-ray imaging, compact objects, X-ray detectors, microchannel plates, astro-ph.IM
Abstract

The Large Observatory For x-ray Timing (LOFT) was studied within ESA M3 Cosmic Vision framework and participated in the final downselection for a launch slot in 2022-2024. Thanks to the unprecedented combination of effective area and spectral resolution of its main instrument, LOFT will study the behaviour of matter under extreme conditions, such as the strong gravitational field in the innermost regions of accretion flows close to black holes and neutron stars, and the supranuclear densities in the interior of neutron stars. The science payload is based on a Large Area Detector (LAD, 10 m2 effective area, 2-30 keV, 240 eV spectral resolution, 1° collimated field of view) and a Wide Field Monitor (WFM, 2-50 keV, 4 steradian field of view, 1 arcmin source location accuracy, 300 eV spectral resolution). The WFM is equipped with an on-board system for bright events (e.g. GRB) localization. The trigger time and position of these events are broadcast to the ground within 30 s from discovery. In this paper we present the status of the mission at the end of its Phase A study.

Published
2014

25. Design of a CZT Gamma-Camera for GRB and Fast Transient Follow-up: a Wide-Field-Monitor for the EDGE Mission

Author

Natalucci, L., Feroci, M., Quadrini, E., Ubertini, P., Piro, L., Herder, J. W. den, Barret, D., Amati, L., Budtz-Jorgensen, C., Caroli, E., Di Cosimo, S., Frutti, M., Labanti, C., Monzani, F., Poulsen, J. M., Nicolini, L., and Stevoli, A.

Subjects
Astrophysics
Abstract

The success of the SWIFT/BAT and INTEGRAL missions has definitely opened a new window for follow-up and deep study of the transient gamma-ray sky. This now appears as the access key to important progresses in the area of cosmological research and deep understanding of the physics of compact objects. To detect in near real-time explosive events like Gamma-Ray bursts, thermonuclear flashes from Neutron Stars and other types of X-ray outbursts we have developed a concept for a wide-field gamma-ray coded mask instrument working in the range 8-200 keV, having a sensitivity of 0.4 ph cm-2 s-1 in 1s (15-150 keV) and arcmin location accuracy over a sky region as wide as 3sr. This scientific requirement can be achieved by means of two large area, high spatial resolution CZT detection planes made of arrays of relatively large (~1cm2) crystals, which are in turn read out as matrices of smaller pixels. To achieve such a wide Field-Of-View the two units can be placed at the sides of a S/C platform serving a payload with a complex of powerful X-ray instruments, as designed for the EDGE mission. The two units will be equipped with powerful signal read out system and data handling electronics, providing accurate on-board reconstruction of the source positions for fast, autonomous target acquisition by the X-ray telescopes., Comment: 9 pages, 7 figures, SPIE Conference on UV, X-ray, and Gamma-Ray Instrumentation for Astronomy, San Diego 26-30 August 2007

Published
2008
Full Text
View/download PDF

26. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO

Author

Di Cosimo, S., Campbell, C., Azim, H.A., Jr., Galli, G., Bregni, G., Curigliano, G., Criscitiello, C., Izquierdo, M., de la Pena, L., Fumagalli, D., Fein, L., Vinholes, J., Ng, W.M.J., Colleoni, M., Ferro, A., Naume, B.J., Patel, A., Huober, J., Piccart-Gebhart, M.J., Baselga, J., and de Azambuja, E.

Published
2018
Full Text
View/download PDF

27. 26P ctDNA prognostic and diagnostic value for recurrence in patients with early-stage breast cancer: A systematic review and meta-analysis

Author

Marta, G. Nader, primary, Monforte, M., additional, Cinquini, M., additional, Agostinetto, E., additional, Branco, D. Martins, additional, Fontsa, M. Langouo, additional, Ignatiadis, M., additional, Torri, V., additional, Apolone, G., additional, Cappelletti, V., additional, Pruneri, G., additional, de Azambuja, E., additional, and Di Cosimo, S., additional

Published
2023
Full Text
View/download PDF

28. 51P Clinical and biological significance of low ERBB2 expression in ductal carcinoma in situ (DCIS) of the breast

Author

Ciniselli, C.M., primary, Verderio, P., additional, Baili, P., additional, Sant, M., additional, De Braud, F.G.M., additional, Folli, S., additional, Scaperrotta, G., additional, De Santis, M.C., additional, Duroni, V., additional, Apolone, G., additional, Vingiani, A., additional, Cappelletti, V., additional, Pruneri, G., additional, and Di Cosimo, S., additional

Published
2023
Full Text
View/download PDF

31. Gene expression profile at week 2 of neoadjuvant therapy course predicts outcome in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO

Author

Di Cosimo, S., primary, Pizzamiglio, S., additional, Sotiriou, C., additional, Ciniselli, C.M., additional, Triulzi, T., additional, de Cecco, L., additional, El-Abed, S., additional, Izquierdo, M., additional, de Azambuja, E., additional, Saura, C., additional, Huober, J., additional, Untch, M., additional, Lang, I., additional, Loi, S., additional, Tagliabue, E., additional, Rubio, I.T., additional, Vingiani, A., additional, Colombo, M.P., additional, Verderio, P., additional, and Pruneri, G., additional

Published
2022
Full Text
View/download PDF

34. 139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial

Author

Rediti, M., primary, Venet, D., additional, Joaquin Garcia, A., additional, Agbor-tarh, D., additional, Maetens, M., additional, Vincent, D., additional, Majjaj, S., additional, El-Abed, S., additional, Liu, M.C., additional, Di Cosimo, S., additional, Piccart, M., additional, Pusztai, L., additional, Loi, S., additional, Salgado, R.F., additional, Viale, G., additional, Rothé, F., additional, and Sotiriou, C., additional

Published
2022
Full Text
View/download PDF

36. LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria

Author

de la Haba Rodriguez, J., Cortés, J., Di Cosimo, S., Blancas López-Barajas, I., Cortez Castedo, S.P., López, A., López-Miranda, E., Pla Juher, H., Albacar Miro, C.R., Ponce, J., Carañana Ballerini, V., Paris Bouzas, L., Valero Arbizu, M., Ruiz Borrego, M.R.B., Iranzo, V., Garrido, A., Alcalá-López, D., Mina, L., Garcia Mosquera, J.J., and Llombart Cussac, A.

Published
2024
Full Text
View/download PDF

37. Rethinking breast cancer follow-up based on individual risk and recurrence management

Author

De Rose, F, Meduri, B, De Santis, M, Ferro, A, Marino, L, Colciago, R, Gregucci, F, Vanoni, V, Apolone, G, Di Cosimo, S, Delaloge, S, Cortes, J, Curigliano, G, De Rose, Fiorenza, Meduri, Bruno, De Santis, Maria Carmen, Ferro, Antonella, Marino, Lorenza, Colciago, Riccardo Ray, Gregucci, Fabiana, Vanoni, Valentina, Apolone, Giovanni, Di Cosimo, Serena, Delaloge, Suzette, Cortes, Javier, Curigliano, Giuseppe, De Rose, F, Meduri, B, De Santis, M, Ferro, A, Marino, L, Colciago, R, Gregucci, F, Vanoni, V, Apolone, G, Di Cosimo, S, Delaloge, S, Cortes, J, Curigliano, G, De Rose, Fiorenza, Meduri, Bruno, De Santis, Maria Carmen, Ferro, Antonella, Marino, Lorenza, Colciago, Riccardo Ray, Gregucci, Fabiana, Vanoni, Valentina, Apolone, Giovanni, Di Cosimo, Serena, Delaloge, Suzette, Cortes, Javier, and Curigliano, Giuseppe

Abstract

Current follow-up policies for early breast cancer aim to detect loco-regional recurrences and manage treatment-related adverse effects. Their "one size fits all" approach does not take into account differences in subtypes at initial diagnosis, individual prognosis and treatments received. They are derived from clinical trials conducted when early detection means - other than mammography - and treatment options were limited. Herein, we address the arguments for re-evaluating current breast cancer follow-up strategies starting from recent advances in breast cancer local and systemic treatments and discussing individual risk of recurrence prediction models, time-adapted imaging and biomarker assessment for disease diagnostic anticipation. This change in perspective would transform breast cancer follow-up into an integrated, multidisciplinary team medical practice. Hence we discuss the important role of patient-centered approaches, but also of general practitioners and other health professionals, in the final promotion of personalized surveillance programs and patient education.

Published
2022

38. Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab

Author

Ligorio, F, Di Cosimo, S, Verderio, P, Ciniselli, CM, Pizzamiglio, S, Castagnoli, L, Dugo, M, Galbardi, B, Salgado, R, Loi, S, Michiels, S, Triulzi, T, Tagliabue, E, El-Abed, S, Izquierdo, M, de Azambuja, E, Nuciforo, P, Huober, J, Moscetti, L, Janni, W, Coccia-Portugal, MA, Corsetto, PA, Belfiore, A, Lorenzini, D, Daidone, MG, Vingiani, A, Gianni, L, Pupa, SM, Bianchini, G, Pruneri, G, Vernieri, C, Ligorio, F, Di Cosimo, S, Verderio, P, Ciniselli, CM, Pizzamiglio, S, Castagnoli, L, Dugo, M, Galbardi, B, Salgado, R, Loi, S, Michiels, S, Triulzi, T, Tagliabue, E, El-Abed, S, Izquierdo, M, de Azambuja, E, Nuciforo, P, Huober, J, Moscetti, L, Janni, W, Coccia-Portugal, MA, Corsetto, PA, Belfiore, A, Lorenzini, D, Daidone, MG, Vingiani, A, Gianni, L, Pupa, SM, Bianchini, G, Pruneri, G, and Vernieri, C

Abstract

BACKGROUND: Despite huge efforts to identify biomarkers associated with long-term clinical outcomes in patients with early-stage HER2-positive breast cancer (HER2+ BC) treated with (neo)adjuvant anti-HER2 therapy, no reliable predictors have been identified so far. Fatty acid uptake, a process mediated by the transmembrane transporter CD36, has recently emerged as a potential determinant of resistance to anti-HER2 treatments in preclinical HER2+ BC models. METHODS: Here, we investigated the association between baseline intratumor CD36 gene expression and event-free survival in 180 patients enrolled in the phase III trial Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO), which randomly assigned stage II-III HER2+ BC patients to receive neoadjuvant lapatinib, trastuzumab, or lapatinib-trastuzumab in combination with chemotherapy. To this aim, we selected NeoALTTO trial patients for whom pretreatment whole transcriptomic data were available. The main study results were validated in an independent cohort of patients enrolled in the neoadjuvant phase II trial NeoSphere. RESULTS: In 180 NeoALTTO patients, high intratumor CD36 expression was independently associated with worse event-free survival in patients treated with trastuzumab-based therapy (hazard ratio [HR] = 1.72, 95% confidence interval [CI] = 1.20 to 2.46), but not with lapatinib-based (HR = 1.02, 95% CI = 0.68 to 1.53) or trastuzumab-lapatinib-based (HR = 1.08, 95% CI = 0.60 to 1.94) therapy. Among 331 NeoSphere patients evaluated, high CD36 expression was independently associated with worse patient disease-free survival in both the whole study cohort (HR = 1.197, 95% CI = 1.002 to 1.428) and patients receiving trastuzumab-based neoadjuvant therapy (HR = 1.282, 95% CI = 1.049 to 1.568). CONCLUSIONS: High CD36 expression predicts worse clinical outcomes in early-stage HER2+ BC treated with trastuzumab-based neoadjuvant therapy.

Published
2022

39. COVID-19 outbreak in Lombardy: Impact on reducing solid cancer diagnoses in 2020

Author

Trama, A, Bernasconi, A, Botta, L, Di Cosimo, S, Miceli, R, Claps, M, Badenchini, F, Lillini, R, Rubino, M, Lasalvia, P, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Di Cosimo, Serena, Miceli, Rosalba, Claps, Melanie, Badenchini, Fabio, Lillini, Roberto, Rubino, Massimiliano, Lasalvia, Paolo, Trama, A, Bernasconi, A, Botta, L, Di Cosimo, S, Miceli, R, Claps, M, Badenchini, F, Lillini, R, Rubino, M, Lasalvia, P, Trama, Annalisa, Bernasconi, Alice, Botta, Laura, Di Cosimo, Serena, Miceli, Rosalba, Claps, Melanie, Badenchini, Fabio, Lillini, Roberto, Rubino, Massimiliano, and Lasalvia, Paolo

Abstract

Our aim was to analyse, on a population level, the year-long decline in cancer diagnoses in the region of Lombardy (Italy), and to characterise the tumours with the greatest reduction in diagnosis by patient age, sex and tumour stage at diagnosis. We used the health care utilisation databases of the Lombardy region to identify cancer patients' characteristics (eg, sex, age) and cancer-related information (eg, cancer site, stage at diagnosis). The frequency of new cancer diagnoses in 2019 and 2020 were compared in terms of percentage differences in undiagnosed cases. We observed two peaks in the decline in cancer diagnoses: March to May 2020 (−37%) and October to December 2020 (−19%). The decline persisted over the course of 2020 and was higher in males and patients aged 74+. Diagnoses of all four common cancers analysed (female breast, lung, colorectal and prostate) remained below pre-pandemic levels. For breast and colorectal cancers, the decline in diagnoses was high in the age groups targeted by population-based screening programmes. We observed a reduction in localised stage cancer diagnoses for all four cancers. Our data confirm that timely monitoring of cancer diagnoses and interventions to prevent disruption of routine diagnostic services are needed to mitigate the impact of emergencies on cancer patients.

Published
2022

40. Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study

Author

Di Cosimo, S., Lupo-Stanghellini, M. T., Costantini, M., Mantegazza, R., Ciceri, F., Salvarani, C., Zinzani, P. L., Mantovani, A., Ciliberto, G., Uccelli, A., Baldanti, F., Apolone, G., Delcuratolo, S., Morrone, A., Locatelli, Franco, Agrati, C., Silvestris, N., Locatelli F. (ORCID:0000-0002-7976-3654), Di Cosimo, S., Lupo-Stanghellini, M. T., Costantini, M., Mantegazza, R., Ciceri, F., Salvarani, C., Zinzani, P. L., Mantovani, A., Ciliberto, G., Uccelli, A., Baldanti, F., Apolone, G., Delcuratolo, S., Morrone, A., Locatelli, Franco, Agrati, C., Silvestris, N., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Importance: Despite people with impaired immune competence due to an underlying disease or ongoing therapy, hereinafter frail patients, are (likely to be) the first to be vaccinated, they were usually excluded from clinical trials. Objective: To report adverse reactions of frail patients after receipt of the third dose (booster) administered after completion of a two-dose mRNA vaccination and to compare with those reported after the receipt of the first two doses. Design: A multicenter, observational, prospective study aimed at evaluating both the safety profile and the immune response of Pfizer-BioNTech or Moderna vaccines in frail patients. Setting: National Project on Vaccines, COVID-19 and Frail Patients (VAX4FRAIL) Participants: People consenting and included in the VAX4FRAIL trial. Exposure: A series of three doses of COVID-19 mRNA vaccination from the same manufacturer. Main outcome(s) and measure(s): Evaluation of a self-assessment questionnaire addressing a predefined list of eight symptoms on a five-item Likert scale. Symptoms were classified as severe if the patient rated them as severe or overwhelming. Results: Among 320 VAX4FRAIL participants diagnosed/treated for hematological malignancies (N=105; 32.8%), solid tumors (N=48; 15.0%), immune-rheumatological diseases (N=60; 18.8%), neurological diseases (N=107; 33.4%), and receiving the booster dose, 70.3% reported at least one loco-regional or systemic reactions. Adverse events were mostly mild or moderate, none being life-threatening. Only six of the 320 (1.9%) patients had their treatment postponed due to the vaccine. The safety profile of the booster compared to previously administered two doses showed a stable prevalence of patients with one or more adverse events (73.5%, 79.7% and 73.9% respectively), and a slightly increment of patients with one or more severe adverse events (13.4%, 13.9% and 19.2% respectively). Conclusions and relevance: The booster of the mRNA COVID-19 vaccine was safely adminis

Published
2022

41. mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients

Author

Lupo-Stanghellini, M. T., Di Cosimo, S., Costantini, M., Monti, S., Mantegazza, R., Mantovani, A., Salvarani, C., Zinzani, P. L., Inglese, M., Ciceri, F., Apolone, G., Ciliberto, G., Baldanti, F., Morrone, A., Sinno, V., Locatelli, Franco, Notari, S., Turola, E., Giannarelli, D., Silvestris, N., Locatelli F. (ORCID:0000-0002-7976-3654), Lupo-Stanghellini, M. T., Di Cosimo, S., Costantini, M., Monti, S., Mantegazza, R., Mantovani, A., Salvarani, C., Zinzani, P. L., Inglese, M., Ciceri, F., Apolone, G., Ciliberto, G., Baldanti, F., Morrone, A., Sinno, V., Locatelli, Franco, Notari, S., Turola, E., Giannarelli, D., Silvestris, N., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Background: Frail patients are considered at relevant risk of complications due to coronavirus disease 2019 (COVID-19) infection and, for this reason, are prioritized candidates for vaccination. As these patients were originally not included in the registration trials, fear related to vaccine adverse events and disease worsening was one of the reasons for vaccine hesitancy. Herein, we report the safety profile of the prospective, multicenter, national VAX4FRAIL study (NCT04848493) to evaluate vaccines in a large trans-disease cohort of patients with solid or hematological malignancies and neurological and rheumatological diseases. Methods: Between March 3 and September 2, 2021, 566 patients were evaluable for safety endpoint: 105 received the mRNA-1273 vaccine and 461 the BNT162b2 vaccine. Frail patients were defined per protocol as patients under treatment with hematological malignancies (n = 131), solid tumors (n = 191), immune-rheumatological diseases (n = 86), and neurological diseases (n = 158), including multiple sclerosis and generalized myasthenia. The impact of the vaccination on the health status of patients was assessed through a questionnaire focused on the first week after each vaccine dose. Results: The most frequently reported moderate–severe adverse events were pain at the injection site (60.3% after the first dose, 55.4% after the second), fatigue (30.1%–41.7%), bone pain (27.4%–27.2%), and headache (11.8%–18.9%). Risk factors associated with the occurrence of severe symptoms after vaccine administration were identified through a multivariate logistic regression analysis: age was associated with severe fever presentation (younger patients vs. middle-aged vs. older ones), female individuals presented a higher probability of severe pain at the injection site, fatigue, headache, and bone pain; and the mRNA-1237 vaccine was associated with a higher probability of severe pain at the injection site and fever. After the first dose, patients presenting a se

Published
2022

43. 2MO Development of a prognostic gene-expression signature for early stage HER2-positive breast cancer patients

Author

Di Cosimo, S., primary, Ciniselli, C.M., additional, Sotiriou, C., additional, Pogue-Geile, K., additional, Fumagalli, D., additional, de Azambuja, E., additional, Venet, D., additional, De Cecco, L., additional, Pong, N., additional, Cappelletti, V., additional, Tagliabue, E., additional, Wang, Y., additional, Saura Manich, C., additional, Nuciforo, P.G., additional, Kuemmel, S., additional, Pusztai, L., additional, Daidone, M.G., additional, Pizzamiglio, S., additional, Pruneri, G., additional, and Verderio, P., additional

Published
2022
Full Text
View/download PDF

45. Design, construction, and test of the Gas Pixel Detectors for the IXPE mission

Author

Baldini, L., primary, Barbanera, M., additional, Bellazzini, R., additional, Bonino, R., additional, Borotto, F., additional, Brez, A., additional, Caporale, C., additional, Cardelli, C., additional, Castellano, S., additional, Ceccanti, M., additional, Citraro, S., additional, Di Lalla, N., additional, Latronico, L., additional, Lucchesi, L., additional, Magazzù, C., additional, Magazzù, G., additional, Maldera, S., additional, Manfreda, A., additional, Marengo, M., additional, Marrocchesi, A., additional, Mereu, P., additional, Minuti, M., additional, Mosti, F., additional, Nasimi, H., additional, Nuti, A., additional, Oppedisano, C., additional, Orsini, L., additional, Pesce-Rollins, M., additional, Pinchera, M., additional, Profeti, A., additional, Sgrò, C., additional, Spandre, G., additional, Tardiola, M., additional, Zanetti, D., additional, Amici, F., additional, Andersson, H., additional, Attinà, P., additional, Bachetti, M., additional, Baumgartner, W., additional, Brienza, D., additional, Carpentiero, R., additional, Castronuovo, M., additional, Cavalli, L., additional, Cavazzuti, E., additional, Centrone, M., additional, Costa, E., additional, D’Alba, E., additional, D’Amico, F., additional, Del Monte, E., additional, Di Cosimo, S., additional, Di Marco, A., additional, Di Persio, G., additional, Donnarumma, I., additional, Evangelista, Y., additional, Fabiani, S., additional, Ferrazzoli, R., additional, Kitaguchi, T., additional, La Monaca, F., additional, Lefevre, C., additional, Loffredo, P., additional, Lorenzi, P., additional, Mangraviti, E., additional, Matt, G., additional, Meilahti, T., additional, Morbidini, A., additional, Muleri, F., additional, Nakano, T., additional, Negri, B., additional, Nenonen, S., additional, O’Dell, S.L., additional, Perri, M., additional, Piazzolla, R., additional, Pieraccini, S., additional, Pilia, M., additional, Puccetti, S., additional, Ramsey, B.D., additional, Rankin, J., additional, Ratheesh, A., additional, Rubini, A., additional, Santoli, F., additional, Sarra, P., additional, Scalise, E., additional, Sciortino, A., additional, Soffitta, P., additional, Tamagawa, T., additional, Tennant, A.F., additional, Tobia, A., additional, Trois, A., additional, Uchiyama, K., additional, Vimercati, M., additional, Weisskopf, M.C., additional, Xie, F., additional, Zanetti, F., additional, and Zhou, Y., additional

Published
2021
Full Text
View/download PDF

46. NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

Author

Jacobs, S, Robidoux, A, Abraham, J, Perez-Garcia, J, La Verde, N, Orcutt, J, Cazzaniga, M, Piette, F, Antolin, S, Aguirre, E, Cortes, J, Llombart-Cussac, A, Di Cosimo, S, Kim, R, Feng, H, Lipchik, C, Lucas, P, Srinivasan, A, Wang, Y, Song, N, Gavin, P, Balousek, A, Paik, S, Allegra, C, Wolmark, N, Pogue-Geile, K, Jacobs S. A., Robidoux A., Abraham J., Perez-Garcia J. M., La Verde N., Orcutt J. M., Cazzaniga M. E., Piette F., Antolin S., Aguirre E., Cortes J., Llombart-Cussac A., Di Cosimo S., Kim R. S., Feng H., Lipchik C., Lucas P. C., Srinivasan A., Wang Y., Song N., Gavin P. G., Balousek A. D., Paik S., Allegra C. J., Wolmark N., Pogue-Geile K. L., Jacobs, S, Robidoux, A, Abraham, J, Perez-Garcia, J, La Verde, N, Orcutt, J, Cazzaniga, M, Piette, F, Antolin, S, Aguirre, E, Cortes, J, Llombart-Cussac, A, Di Cosimo, S, Kim, R, Feng, H, Lipchik, C, Lucas, P, Srinivasan, A, Wang, Y, Song, N, Gavin, P, Balousek, A, Paik, S, Allegra, C, Wolmark, N, Pogue-Geile, K, Jacobs S. A., Robidoux A., Abraham J., Perez-Garcia J. M., La Verde N., Orcutt J. M., Cazzaniga M. E., Piette F., Antolin S., Aguirre E., Cortes J., Llombart-Cussac A., Di Cosimo S., Kim R. S., Feng H., Lipchik C., Lucas P. C., Srinivasan A., Wang Y., Song N., Gavin P. G., Balousek A. D., Paik S., Allegra C. J., Wolmark N., and Pogue-Geile K. L.

Abstract

Purpose: The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2+) breast cancer patients treated with neoadjuvant trastuzumab or neratinib or the combination and weekly paclitaxel followed by standard doxorubicin plus cyclophosphamide. The secondary aims include biomarker analyses. Experimental design: pCR was tested for association with treatment, gene expression, and a single nucleotide polymorphism (SNP) in the Fc fragment of the IgG receptor IIIa-158V/F (FCGR3A). Pre-treatment biopsies and residual tumors were also compared to identify molecular changes. Results: The numerical pCR rate in the trastuzumab plus neratinib arm (50% [95%CI 34-66%]) was greater than that for single-targeted therapies with trastuzumab (38% [95%CI 24-54]) or neratinib (33% [95%CI 20-50]) in the overall cohort but was not statistically significant. Hormone receptor-negative (HR-) tumors had a higher pCR rate than HR+ tumors in all three treatment arms, with the highest pCR rate in the combination arm. Diarrhea was the most frequent adverse event and occurred in virtually all patients who received neratinib-based therapy. Grade 3 diarrhea was reported in 31% of patients; there were no grade 4 events. Our 8-gene signature, previously validated for trastuzumab benefit in two different clinical trials in the adjuvant setting, was correlated with pCR across all arms of NSABP FB-7. Specifically, patients predicted to receive no trastuzumab benefit had a significantly lower pCR rate than did patients predicted to receive the most benefit (P = 0.03). FCGR genotyping showed that patients who were homozygous for the Fc low-binding phenylalanine (F) allele for FCGR3A-158V/F were less likely to achieve pCR. Conclusions: Combining trastuzumab plus neratinib with paclitaxel increased the absolute pCR rate in the overall cohort and in HR- patients. The 8-gene signature, which is validated for predicting trastuzumab benefit in t

Published
2019

47. The LOFT Mission Concept - A Status Update

Author

Feroci, M, Bozzo, E, Brandt, S, Hernanz, M, van Der Klis, M, Liu , L. -P, Orleanski, P, Pohl, M, Santangelo, A, Schanne, S, Stella, L, Takahashi, T, Tamura, H, Watts, A, Wilms, J, Zane, S, Zhang, S. -N, Bhattacharyya, S, Agudo, I, Ahangarianabhari, M, Albertus, C, Alford, M, Alpar, A, Altamirano, D, Alvarez, L, Amati, L, Amoros, C, Andersson, N, Antonelli, A, Argan, A, Artigue, R, Artigues, B, Atteia, J. -L, Azzarello, P, Bakala, P, Ballantyne, D. R, Baldazzi, G, Baldo, M, Balman, S, Barbera, M, van Baren, C, Barret, D, Baykal, A, Begelman, M, Behar, E, Behar, O, Belloni, T, Belluti, P, Bernardini, F, Bertuccio, G, Bianchini, A, Binko, P, Blay, P, Bocchino, P, Bode, M, Bodin, P, Bombaci, I, Bonnet Bidaud, J. -M, Schnittman, Jeremy David, Borghi, G, Boutloukos, N, Bouyjou, F, Bradley, L, Braga, J, Briggs, M. S, Brown, E, Buballa, M, Bucciantini, N, Burderi, L, Burgay, M, Bursa, M, Budtz-Jorgensen, C, Cackett, E, Cadoux, F. R, Cais, P, Caliandro, G. A, Campana, R, Campana, S, Cao, X, Capitanio, F, Casares, J, Casella, P, Castro-Tirado, A. J, Cavazzuti, E, Cavechi, Y, Celestin, S, Cerda-Duran, P, Chakrabarty, D, Chamel, N, Chateau, F, Chen, C, Chen, Y, Chenevez, J, Chernyakova, M, Coker, J, Cole, R, Collura, A, Coriat, M, Cornelisse, R, Costamante, L, Cros, A, Cui, W, Cumming, A, Cusumano, G, Czerny, B, D'Ai, A, D'Ammando, J. P. C, D'Elia, V, Dai, Z, Del Monte, E, De Luca, A, De Martino, D, Dercksen, J. P. C, De Pasquale, M, De Rosa, A, Del Santo, M, Di Cosimo, S, Degenaar, N, den Herder, J. W, Diebold, S, Di Salvo, T, Dong, Y, Donnarumma, I, Doroshenko, V, Doyle, G, Drake, S. A, Durant, M, Emmanoulopoulos, D, Enoto, T, Erkut, M. H, Esposito, P, Evangelista, Y, Fabian, A, Falanga, M, Favre, Y, Feldman, C, Fender, R, Feng, H, Ferrari, V, Ferrigno, C, Ficorella, F, Finger, M, Finger, M. H, Fraser, G. W, Frericks, N, Fullekrug, M, Fuschino, F, Gabler, M, Galloway, D. K, Galvez Sanchez, J. L, Gandhi, P, Gao, Z, Garcia-Berro, E, Gendre, B, Gevin, O, Gezari, S, Giles, A. B, Gilfanov, M, Giommi, P, Giovannini, G, Giroletti, M, Gogus, E, Goldwurm, A, Goluchova, K, Gotz, D, Gou, L, Gouiffes, C, Grandi, P, Grassi, M, Greiner, J, Grinberg, V, Groot, P, Gschwender, M, Gualtieri, L, Guedel, M, Guidorzi, C, Guy, L, Haas, D, Haensel, P, Hailey, M, Hamuguchi, K, Hansen, F, Hartmann, D. H, Haswell, C. A, Hebeler, K, Heger, A, Hempel, M, Hermsen, W, Homan, J, Hornstrup, A, Hudec, R, Huovelin, J, Huppenkothen, A, Inam, S. C, Ingram, A, in't Zand, J. J. M, Israel, G, Iwasawa, K, Izzo, L, Jacobs, H. M, Jetter, F, Johannsen, T, Jenke, P. A, Jonker, P, Jose, J, Kaaret, P, Kalamkar, M, Kalemci, E, Kanbach, G, Karas, V, Karelin, D, Kataria, D, Keek, L, Kennedy, T, Klochkov, D, Kluzniak, W, Koerding, E, Kokkotas, K, Komossa, S, Korpela, S, Kouveliotou, C, Kowalski, A. F, Kreykenbohm, I, Kuiper, L. M, Kunneriath, D, Kurkela, A, Kuvvetli, I, La Franca, F, Labanti, C, Lai, D, Lamb, F. K, Lachaud, C, Laubert, P. P, Lebrun, F, Li, X, Liang, E, Limousin, O, Lin, D, Linares, M, Linder, D, Lodato, G, Longo, F, Lu, F, Lund, N, Maccarone, T. J, Macera, D, Maestre, S, Mahmoodifar, S, Maier, D, Malcovati, P, Malzac, J, Malone, C, Mandel, D, Mangano, V, Manousakis, A, Marelli, M, Margueron, J, Marisaldi, M, Markoff, S. B, Markowitz, A, Marinucci, A, Martindale, A, Martinez, G, McHardy, I. M, Medina-Tanco, G, Mehdipour, M, Melatos, A, Mendez, M, Mereghetti, S, Migliari, S, Mignani, R, Michalska, M, Mihara, T, Miller, M. C, Miller, J. M, Mineo, T, Miniutti, G, Morsink, S, Motch, C, Motta, S, Mouchet, M, Mouret, G, Mulacova, J, Muleri, F, Munoz-Darias, T, Negueruela, I, Neilsen, J, Neubert, T, Norton, A. J, Nowak, M, Nucita, A, O'Brien, P, Oertel, M, Olsen, P. E. H, Orienti, M, Orio, M, Orlandini, M, Osborne, J. P, Osten, R, Ozel, F, Pacciani, L, Paerels, F, Paltini, S, Paolillo, M, Papadakis, I, Papitto, A, Paragi, Z, Paredes, J. M, Patruno, A, Paul, B, Pederiva, F, Perinati, E, Pellizzoni, A, Penacchioni, A. V, Peretz, U, Perez, M. A, Perez-Torres, M, Petersen, B. M, Petracek, V, Picciotto, A, Piemonte, C, Pittori, C, Pons, J, Portell, J, Possenti, A, Postnov, K, Poutanen, J, Prakash, M, Prandoni, I, Provost, H. Le, Psaltis, D, Pye, J, Qu, J, Rambaud, D, Ramon, P, Ramsay, G, Rapisarda, M, Rachevski, A, Rashevskaya, I, Ray, P. S, Rea, N, Reddy, S, Reig, P, Reina, M. Aranda, Remillard, R, Reynolds, C, Rezzolla, L, Ribo, M, Rie, R. de la, Riggio, A, Rios, A, Rischke, D. H, Rodríguez-Gil, P, Rodriguez, J, Rohlfs, R, Romano, P, Rossi, E. M .R, Rozanska, A, Rousseau, A, Rudak, B, Russell, D. M, Ryde, F, Sabau-Graziati, L, Sakamoto, T, Sala, G, Salvaterra, R, Salvetti, D, Sanna, A, Sandberg, J, Savolainen, T, Scaringi, S, Schaffner-Bielich, J, Schatz, H, Schee, J, Schmid, C, Serino, M, Shakura, N, Shore, S, Schnittman, J. D, Schneider, R, Schwenk, A, Schwope, A. D, Sedrakian, A, Seyler, J.-Y, Shearer, A, Slowikowska, A, Sims, M, Smith, A, Smith, D. M, Smith, P. J, Sobolewska, M, Sochora, V, Soffitta, P, Soleri, P, Song, L, Spencer, A, Stamerra, A, Stappers, B, Staubert, R, Steiner, A. W, Stergioulas, N, Stevens, A. L, Stratta, G, Strohmayer, T. E, Stuchlik, Z, Suchy, S, Suleimanov, V, Tamburini, F, Tauris, T, Tavecchio, F, Tenzer, C, Thielemann, F. K, Tiengo, A, Tolos, L, Tombesi, F, Tomsick, J, Torok, G, Torrejon, J. M, Torres, D. F, Torresi, E, Tramacere, A, Traulsen, I, Trois, A, Turolla, R, Turriziani, S, Typel, S, Uter, P, Uttley, P, Vacchi, A, Varniere, P, Vaughan, S, Vercellone, S, Vietri, M, Vincent, F. H, Vrba, V, Walton, D, Wang, J, Wang, Z, Watanabe, S, Wawrzaszek, R, Webb, N, Weinberg, N, Wende, H, Wheatley, P, Wijers, R, Wijnands, R, Wille, M, Wilson-Hodge, C. A, Winter, B, Walk, S. J, Wood, K, Woosley, S. E, Wu, X, Xiao, L, Xu, R, Yu, W, Yuan, F, Yuan, W, Yuan, Y, Zampa, G, Zampa, N, Zampieri, L, Zdunik, L, Zdziarski, A, Zech, A, Zhang, B, Zhang, C, Zhang, S, Zingale, M, Zorzi, N, and Zwart, F

Subjects
Astrophysics
Abstract

The Large Observatory For x-ray Timing (LOFT) is a mission concept which was proposed to ESA as M3 and M4 candidate in the framework of the Cosmic Vision 2015-2025 program. Thanks to the unprecedented combination of effective area and spectral resolution of its main instrument and the uniquely large field of view of its wide field monitor, LOFT will be able to study the behaviour of matter in extreme conditions such as the strong gravitational field in the innermost regions close to black holes and neutron stars and the supra-nuclear densities in the interiors of neutron stars. The science payload is based on a Large Area Detector (LAD, is greater than 8m2 effective area, 2-30 keV, 240 eV spectral resolution, 1 degree collimated field of view) and a Wide Field Monitor (WFM, 2-50 keV, 4 steradian field of view, 1 arcmin source location accuracy, 300 eV spectral resolution). The WFM is equipped with an on-board system for bright events (e.g., GRB) localization. The trigger time and position of these events are broadcast to the ground within 30 s from discovery. In this paper we present the current technical and programmatic status of the mission.

Published
2016
Full Text
View/download PDF

48. 131P Impact of body mass (BMI) and weight change after adjuvant treatment in patients (pts) with HER2-positive early breast cancer

Author

Franzoi, M.A., primary, Martel, S., additional, Agbor-Tarh, D., additional, Piccart, M., additional, Bines, J., additional, Loibl, S., additional, Di Cosimo, S., additional, Vaz-Luis, I., additional, Di Meglio, A., additional, Del Mastro, L., additional, Gombos, A., additional, Desmedt, C., additional, Jerusalem, G., additional, Reaby, L., additional, Pienkowski, T., additional, Lambertini, M., additional, and de Azambuja, E., additional

Published
2021
Full Text
View/download PDF

50. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial

Author

Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im Y, Valeria Bianchi G, Galbardi B, Dugo M, De Cecco L, Tseng L, Liu M, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh D, Poirier B, Valagussa P, Gianni L, and Tagliabue E

Abstract

As most erb-b2 receptor tyrosine kinase 2 (HER2)-positive breast cancer (BC) patients currently receive dual HER2-targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting post-surgical salvage therapy, are needed. Herein, we evaluated the 41-gene classifier trastuzumab advantage risk model (TRAR) as a predictive marker for patients enrolled in the NeoSphere trial. TRAR scores were computed from RNA of 350 pre- and 166 post-treatment tumor specimens. Overall, TRAR score was significantly associated with pathological complete response (pCR) rate independently of other predictive clinico-pathological variables. Separate analyses according to estrogen receptor (ER) status showed a significant association between TRAR score and pCR in ER-positive specimens but not in ER-negative counterparts. Among ER-positive BC patients not achieving a pCR, those with TRAR-low scores in surgical specimens showed a trend for lower distant event-free survival. In conclusion, in HER2-positive/ER-positive BC, TRAR is an independent predictor of pCR and represents a promising tool to select patients responsive to anti-HER2-based neoadjuvant therapy and to assist treatment escalation and de-escalation strategies in this setting. This article is protected by copyright. All rights reserved.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results